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Abstract
As Canada's population ages, the proportion of the population that is taking multiple medications 
will increase. A way to limit the number of adverse drug reactions for those on multiple 
medications is to have their medication regime reviewed by a health professional regularly. The 
current study utilizes both traditional and mixed linear analyses to examine the relationship 
between the lack of medication review and a number o f health outcome measures on a dataset 
containing 76 810 subjects. The results indicate that differences exist for those who have not had 
their medications reviewed, clustering effects are significant, and the health outcome measures 
examined are influenced by whether or not one has received a medication review in the last 6 
months.
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Introduction
The population o f Canada is aging. Along with the increase in the average age o f the 
population will come an increase in the prevalence of chronic disease, with a subsequent increase 
in medication use. As a result, Canada will have more seniors then ever who have multiple 
disease diagnoses and are taking a number of different prescription medications to deal with their 
health issues. Taking multiple medications, combined with age-related increased drug sensitivity 
and an increased probability of predisposing conditions, increases the likelihood of adverse drug 
reactions. Because o f this increased probability o f medication troubles, medication reviews 
performed by qualified health workers are necessary for this population and should performed 
regularly.
One segment o f the older population in which medication reviews are essential is that of 
the people receiving home care. These individuals require care but do not receive their care 
within an institutional setting. As such, their medications are often prescribed, administered, and 
monitored by a number o f different health professionals that ai'e frequently uncoordinated which 
leaves these clients at risk o f having adverse drug reactions.
For individuals receiving services from Community Care Access Centres (CCACs) 
Ontario, individual routine clinical data is taken using the Minimum Data Set-Home Care 
(MDS_HC) tool that has been developed by the interRAI team of researchers (InterRAI, 2008). 
Within the MDS-HC, there is one item that pertains to medication reviews. It is titled medication 
oversight and refers to a lack of medication review for the client. This item measures whether or 
not a physician reviewed the client’s mediations as a whole in the last 180 days (or since last 
assessment). Due to the importance of medication reviews, the medication oversight item was 
used as a Home Care Quality Indicator (HCQI). HCQIs were constructed in order to be used by
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Community Care Access Centres to support evidence based decision making related to the 
quality of home care services (Elirdes et al., 2004).
From the FlCQl system in place in Ontario, it was reported that home care patients within 
the district o f Thunder Bay had a higher than expected rate of medical oversights. To explore 
these issues further, data on Ontario home care patients will be used collected using the MDS- 
FIC assessment tool. This current exploration into the MDS-FIC data will reveal results such as 
provincial prevalence of medication oversight, and its effect on a number o f outcome measures.
The introduction to this thesis has been organized in the following fashion. To begin, a 
general overview of the population demographics and their implications to medications will be 
presented; followed by a section on medications and medication reviews; and it will conclude 
with a review of routine organizational data and their use in research.
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Population Demographics 
Within Canada, the senior population has been growing faster than all others age groups. 
The 2006 population census estimated that there were 4.33 million Canadians over the age of 65. 
an 80% increase from the 1981 estimate of 2.4 million (Statistics Canada, 2008). In fact, the 
senior population has grown almost twice as fast as the general population since the 1981 census. 
As a result of this growth, the proportion o f Canadians over the age o f 65 has now reached 
13.5% (Statistics Canada, 2008) and it has been forecasted to reach 17.7% by the year 2026 
(Health Canada, 2003).
This growth trend also can be seen in the average age of the population. The 2006 
Census confirmed the median age of the population to have reached an all time high o f 39.5 
years of age (Statistics Canada, 2008). This is has increased from 35.3 in 1996 and 37.6 in 2001 
(Statistics Canada, 2008). The median age is the point where exactly one half of the population 
is older, and the other half is younger. Because the median age is increasing, one could expect 
change to occur in many areas of life including Canada’s health care system, social services, 
labour force, and economy. This trend of an increasing age of our nation is expected continue 
and to accelerate over the upcoming decades as the “baby boomer” generation enters into senior- 
hood. By the year 2056, the projected percentage of the population of Canada over the age of 65 
is to have reached over 25% (Statistics Canada, 2008).
The baby boom generation can be defined as individuals bom during the years following 
World War II, I946-I965 (Turcotte & Schellenberg, 2006). During these years, birth rates 
skyrocketed in a number of countries around the world, including Canada and the United States. 
This increase in births after the war was followed by a steady decline in birthrate after the mid 
1960s has left a massive bulge in the age demographics of the population (Statistics Canada,
Exploring Medication Oversight 10
2008; Turcotte & Schellenberg, 2006). Over sixty years ago, this demographic bulge affected 
the age make up of the population by drastically decreasing the median age. And over time, as 
this “baby boomer” generation has aged, society has had to deal with a multitude o f different 
effects on labour, the economy, and the health care system. Consequently, we are now about 
reach a new era for this generation, as the oldest o f the “baby boomers” will soon become 
seniors.
Figure 1. Age Pyramid o f  Canada for 1966, and 2006.
Source: Statistics Canada (2008)
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It is because of this “baby boomer” generation, combined with longer life expectancies 
and low fertility rates, that we see this drift in the age of our nation (Turcotte & Schellenberg, 
2006). This trend can also be looked at from a provincial standpoint with differences occurring 
between the provinces and territories. The province of Alberta, due to the migratory influx of 
young workers and a high fertility rate, is Canada’s youngest province with a median age o f 35.5
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years (Statistics Canada, 2008). Contrarily, the province of Newfoundland and Labrador is the 
oldest province with a median age 41.3 years (Statistics Canada. 2008). In Ontario, the province 
o f interest for this thesis, the median age in 2006 was 39.0 years, one half a year less than the 
nation’s average (Statistics Canada, 2008).
The trend of an increasing proportion of seniors can also be found within Ontario’s 
demographic makeup (Fig. 2). In the year 2000, the percentage of the Ontario population who 
were seniors was 12.6% (Government o f Ontario, 2008b). Some recent governmental reports 
have estimated that the senior population of Ontario will double in the next 16 years 
(Government of Ontario, 2008b).
Figure 2. Population o f  Ontario by Age Category 2006 
Source: Statistics Canada (2008)
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However, this increase in the average age is not uniformly affecting all areas in the 
province of Ontario. Some areas, such as the Niagara area and the North ai'e aging faster than 
the highly populated areas o f Southern Ontario. Erom the 2001 census, Ontario had four o f the 
top 10 youngest Census Metropolitan Areas (CMAs) in Canada (Government of ON, 2008a). 
These areas were Toronto, Oshawa, Windsor, and Kitchener with Kitchener being the youngest 
CMA in Ontario with a median age o f 35.3 (Government of ON, 2008a). On the other hand, 
Ontario also had 4 o f the top ten oldest metropolitan areas in Canada. These areas were 
Kingston, Greater Sudbury, Thunder Bay, and St. Catherines-Niagara (Government o f ON, 
2008a). The oldest city in Ontario was Elliot Lake, with a median age of 49.4 years in 2001 
(Government o f ON, 2008a). Erom this, one could draw together that the implications of an 
aging society will have a varying affect from region to region.
Due to this demographic bulge in the population of Ontario and the nation of Canada, 
issues and challenges will arise that will need to be taken on by researchers of all disciplines. 
Research into such challenges should and must be done in order to minimize the negative effects 
on the expanding older population. It is important to reduce such harmful effects that will 
impact all Canadians and on all levels of government.
Implications for Health
The aging trend occurring currently in Canada is expected to raise a number of challenges 
in many facets o f Canadian society including the economy, the workforce, and social 
programming (Turcotte & Schellenberg, 2006). One major area of concern that will arise as the 
large cohort o f people becomes older is the health of, and health services for, the older 
population. While seniors are generally living longer than they did in the past, the older
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population is still more likely than youth to endure health problems and experience chronic 
diseases (National Advisory Council on Aging, 2006). Health problems at an older age can lead 
to a loss of self-sufficiency, independence and control over their every day activities. Therefore, 
it is not surprising that those over the age of 65 use the health care system more than any other 
age group (Rotermann, 2003).
When examining the current status of the health o f Canadian seniors, some aspects of 
their health have been improving over the recent years. These include life expectancy at the age 
of 65, the prevalence of heart disease, and malnutrition (National Advisory Council on Aging, 
2006). For example, between 1999 and 2003, life expectancy increased by 1 year for men and 
by 0.6 years for women (National Advisory Council on Aging, 2006). There are other aspects in 
the health o f seniors that are declining in recent years. The rate o f having one or more chronic 
diseases is rising, as are the obesity rates (National Advisory Council on Aging, 2006). Related 
to the increased obesity rates is the ever-increasing rate o f diabetes in the senior population.
From 2001 to 2005, the diabetes prevalence rate among seniors raised two percent from 13% to 
15% (National Advisory Council on Aging, 2006). Areas that have remained stable include 
physical activity, suicide among elderly males and falls (National Advisory Council on Aging, 
2006).
In order to support older people as they age, the government o f Ontario has developed a 
continuum of care that assist people in different ways depending on their individual needs. This 
continuum ranges from supportive and home care services, to supportive housing, and eventually 
long-term care homes (Ontario Home Care Association, 2008).
For this thesis, the element o f the care continuum that is focused on is home care. Home 
care consists of a variety o f health and care services offered by different providers to individuals
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in their place o f residence. These include but are not exclusive to chronic disease treatment, 
illness prevention, health promotion, assistance with activities of daily living, rehabilitation, and 
disease diagnosis (Ontario Association o f Community Care Access Centres, 2008). By 
providing these services, home care functions as a bridge between the different care settings 
including acute care, emergency rooms, long term care hospitals and hospices.
In the province o f Ontario, home care is publicly funded and has emerged as an integral 
component o f the health care system. In 1996, the Ministry of Health and Long-term Care 
established a system of 43 Community Care Access Centres (CCACs) in order to assist the 
public in accessing government-funded services offered in the continuum of care. Since the 
development o f Local Health Integrated Networks (LHINs), the 43 CCACs have been narrowed 
down and aligned to match the 14 geographical areas within the THIN system (Government of 
Ontario, 2008c).
CCACs are responsible for determination of eligibility and access with regards to the 
continuum of care. Every year in Ontario, the Community Care Access Centres provide 
coordinated access to health and support services to approximately 500,000 clients, and provides 
services daily to approximately 185,000 Ontarians in their communities (OACCAC, 2007).
Medications
Each year, Canadians are prescribed over 400 million medications and spend 
approximately $770 each on their medications (Sketris, Ingram, & Lummis, 2003). In terms of 
the population, Canadians spend $24.8 billion dollars a year on medications. A study performed 
by Canadian Insitutue for Health Information (CIHI, 2007) found that drugs have been one o f the 
fastest growing components of total health expenditures in Canada. Between the years of 1985
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and 2005, the average annual growth rate of total health expenditures was 6.5%. During the 
same time period, the average growth rate in drug expenditures was 9.5%. In per capita terms, 
drug expenses increased from $147 per person in 1985, to $723 per person in 2005. Although 
these figures and numbers are for the general Canadian public, a large proportion relates to the 
senior population, as those over the age o f 65 are the major consumers of medications within 
Canada (CIHI, 2007). One can only assume that these medication trends will continue and even 
increase the next decade as the demographic bulge ages.
With the increase in number of chronic conditions and health problems that occur in aged 
individuals, it is not uncommon for those over the age of 65 to be on a number of different 
prescription medicines. This use of multiple prescriptions is referred to as polypharmacy. 
Statistics Canada data shows that in 1994/1995, 10% of Canadians aged 65-74 and 13% of those 
aged 75 and over were multiple medication users (Millar, 1998). Statistics Canada reported that 
27% of elderly women and 16% of elderly men took at least 5 different types of medications 
(Rotermann, 2003).
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Medication Metabolism and Physiological Changes Associated with Age
As individuals grow older, a number of physiological changes occur. These bodily 
changes affect not only how the body performs on a daily basis but also have a great effect on 
how drugs act once they have entered the bodily system (known as pharmacokinetics) and their 
eventual outcomes. According to Taliaferro (2001), the five changes that have a large effect on 
phai'macokinetics in geriatric patients are:
1. An increase in body fat: The increase in body fat will affect a drug that is lipid 
soluble causing them to have a broader and prolonged distribution.
2. A decrease in body fluid: Any decrease in bodily fluid could result in a higher 
concentration of a drug within the body.
3. A decrease in action o f the gastrointestinal tract: Because the contents of the 
gastrointestinal tract move slower in old age, the action o f medications may be 
delayed or decreased.
4. A decrease in liver function: A less functioning liver could potentially result in an 
accumulation of medications within the liver and may lead to toxicity.
5. A decrease in kidney function: A decrease in kidney function leads to slower 
excretion of medications.
These age-related changes affect the absorption, distribution, protein binding, metabolism, 
excretion, and dosage sensitivity of the medications consumed in the older adult (Hutchison &
O’Brian, 2007). When compared to a younger adult, the same medication being consumed by an 
older person can behave differently within the body and lead to different outcomes. An 
awareness of these physiological effects helps in the understanding of why medications become
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a health issue in the older population, why some medications cause adverse reactions, and why 
some prescription medications can be considered inappropriate for the older population.
Adverse Drug reactions
With multiple medications comes an increased chance of adverse drug reactions (ADRs). 
ADRs can be defined as any noxious, unintended, and undesired effect of a drug, which occurs at 
doses used in humans for prophylaxis, diagnosis, or therapy (WHO, 1998). ADRs are more 
common in older persons due to the previously mentioned increases in the number and 
combination medications being taken, as well as age-related sensitivity to drug effects and the 
prevalence o f predisposing conditions. These factors have been shown to increase the frequency 
and severity of adverse drug reactions (Ray, Griffin, & Shore, 1990). O f the adverse drug 
reactions in Canada, older adults experience a vast share of them, which lead to a list of 
undesirable outcomes such as falls, hip fractures, delirium, and urticaria (Gurwitz et al., 2000). 
Approximately one in three older persons taking at least five medications will experience an 
adverse drug event each year with about two-thirds those patients requiring medical attention 
(Hanlon et al., 1997). It has also been found that over 90% of these ADRs are predictable, and 
about 28% are preventable (Gurwitz et al., 2003). Research has clearly demonstrated that not 
only are adverse drug events common but they are predictable and therefore, preventable.
A 2003 study performed by Juurlink et al. (2003) examined drug-to-drug interactions in 
Ontarians over the age of 65. This study investigated three different drug combinations and 
found that 2-8% of the hospitalizations studied could have been prevented if the patients had not 
been receiving medications that are known to lead to adverse drug reactions.
The Canadian Adverse Events Study (Baker et al., 2003) found that after reviewing 3745
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hospital charts, 40.8% had at least one screening criterion for an adverse drug event (ADE) and 
that among patients with ADEs, 36.9% were retrospectively judged to be preventable. Baker et 
al. concluded that the incidence rate of 7.5% for ADE associated hospitalizations in their study 
suggests that 185 000 of the 2.5 million annual hospital admissions are associated with an ADE 
and close to 70 000 of these hospitalizations are potentially preventable. In a 2002 review 
article, Patel and Zed stated that 28% of all emergency room visits were drug related. O f those 
visits, 24% resulted in hospital admission (Patel & Zed, 2002).
As the literature has demonstrated, adverse drug reactions are incredibly common amongst 
older individuals and can be prevented when the proper measures are put into place.
Inappropriate Medications
Inappropriate medications can be defined as medications whose risk o f adverse effects 
poses a greater threat to an individual than the possible positive health benefits that they may 
provide (Pick et al., 2003). Inappropriate prescribing and inappropriate medication use occurs 
frequently within the elderly population. A study by Howard et al. (2004) found that the 
prevalence of potentially inappropriate medications was 16.3% in a sample o f 889 elderly 
patients in southern Ontario. The prevalence rates o f inappropriate medication use has been 
shown to as high or higher in other countries: 12-40% in a number o f different older populations 
within the U.S. (Zhan et al., 2001), approximately 20% in home care populations in a number of 
different European countries (Fialova et al., 2005), and 21% in Japan (Niwata, Yukari, & 
Ikegami, 2006).
The use of an inappropriate medication can lead to a number of negative outcomes 
including adverse drug reactions, falls, fractures, orthostatic hypertension, prolonged sedation.
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hospitalization, and possibly death (Fu. Liu, & Christensen, 2004). A 2005 study looking at 
3372 nursing home residents found that those receiving inappropriate medications had greater 
odds of being hospitalized (Lau et al., 2005). This study also found that residents with 
intermittent inappropriate medication exposure were at greater odds of death that those with no 
exposure (Lau et al., 2005).
One can conclude from the prevalence figures that inappropriate medication prescribing 
and their use is a major problem for the elderly population all over the globe. These medications 
on their own can have a deleterious effect on a individual’s health. Many studies have been 
conducted that look and the prevalence of this problem and at the effect of specific drugs with 
their particular related adverse effects on the elderly individuals.
One study performed by Liu, Fu, and Christensen (2004) explored the relationship between 
inappropriate medication and health outcomes at a national level. This group used the Beers 
criteria to identify potentially inappropriate medication (PIM). For their research they used 
secondary data gathered by the 1996 Medical Expenditure Panel Survey data set. This survey 
data provided nationally representative estimates of healthcare utilization, expenditures, sources 
o f payment, and insurance coverage for the non-institutionalized elderly population. A 5-point 
scale question looking at perceived health status was used as the dependent variable in their 
analyses. They found that after controlling for a set of possible confounding variables, 
individuals who were using inappropriate medications at time 1 had a significantly lower score at 
time 2 on their self-perceived health status than those not using inappropriate medications. Other 
risk factors that were found to also predict a lower score on the dependent variable were a higher 
number o f prescriptions, being black, having low education, and having one or more chronic 
diseases. Fiu, Liu and Christensen (2004) concluded that their study provided strong evidence
Exploring Medication Oversight 20
that inappropriate medication use is associated with a subsequent decrease in self-perceived 
health status in the elderly.
Falls and Iniuries
Another way that medications can affect the health of the elderly is their relationship with 
falls and hip fractures. Because of their many side effects, drugs can increase the risk o f falling 
through sedative properties, balance impairment, delayed reaction times, unintentional lowering 
of blood pressure, drug-induced Parkinsonian symptoms, and a variety of other mechanisms. The 
cost to an older person’s health after a fall is colossal. Falls can cause death, continuing 
disability, chronic pain, depression, institutionalization, and a fear o f falling (Grisso et al., 1990, 
Nevitt et al., 1991, Tinetti, Mednes de Leon et al., 1994). A fear o f falling can lead to 
withdrawal from activities, which will most likely have a negative effect on health status (Tinetti, 
Mednes de Leon et al., 1994).
A study was performed in 1998 that looked at drug use, cognitive status, and falls in a 
population of Swedish women over the age of 75 (Guo, Wills, Viitanen, Fastbom & Winblad, 
1998). This study found that those women who were cognitively impaired and taking opioid 
analgesics were twice as likely to fall. The foremost opioid analgesic prescribed to this 
population was propoxyphene. Propoxyphene, which is on the Beers Criteria List 1, has been 
declared inappropriate for the elderly because of its strong narcotic side effects with little more 
pain suppression than that o f acetaminophen. This is just one example o f a drug that is known to 
have negative side effects to be continually prescribed by doctors to elderly patients.
Inappropriate drugs can directly affect one’s health status as well as indirectly through 
causing them to have a fall. In the next section, the effect of unsuitable drugs on the elderly
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population is reviewed.
Cognitive Status and Medications
One particularly large group of commonly used drugs that often cause problems in the 
elderly is anticholinergics. Anticholinergics are daigs that block the action of the 
neurotransmitter acetylcholine and are prescribed for clinical disorders such as Parkinson’s 
disease and bladder Incontinence (Lechevallier-Michel, Molimard, Dartigues, Fabrigoule, & 
Fourrier-Reglat, 2004). When used with seniors, anticholinergic drugs may cause a wide variety 
of side effects that may be able to be misinterpreted as part of the normal aging process such as 
dry mouth, nausea, blurred vision, and rapid heart rate, among many others. On top of those 
unwanted side effects, recent research points that anticholinergic drugs have a negative effect on 
the cognitive status of older people. In a 2006 study performed by Ancelin et al. (2006), it was 
found that 10% of the community dwelling elderly in their study used anticholinergic drugs 
regularly and o f those individuals, 80% performed poorly on a cognitive test (Mini-Mental State 
Examination) compared to 35% of non-users.
A second study examining drugs and cognition was conducted to examine the association 
between the use of drugs with anticholinergic properties and cognitive performance in an elderly 
population (Lechevallier-Michel et al., 2004). The sample contained 1780 community dwelling 
subjects over the age of 70 and also made use the Mini-Mental State Examination as the 
cognitive test. After controlling for confounding factors, it was found that anticholinergic drug 
use was significantly associated with low cognitive performance.
A third and more recent study from 2007 demonstrated that seniors who took 
anticholinergic drugs had more memory impairment than non-users, and they also performed
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significantly more poorly on tests of balance and physical function (Hilmer et ah, 2007). Their 
findings suggest that not only do anticholinergic drugs impair the ability o f seniors to function 
mentally, but they may also impair them physically.
Functioning Ability
As individuals age, age-related biological changes can affect not only the way medications 
react within the body, but can also cause a decrease in the ability to function and perform their 
everyday tasks. It is has been found that inappropriate medications can have serious negative 
effect on the elderly population and their every day functioning.
Landi et al. (2007) examined a population o f frail elderly Italians living in the community 
to explore the relationship between inappropriate medications and measures of physical 
performance, muscle strength, and functional status. The average age of the population was 85.8 
years and based on the 2003 Beers criteria, 26% of the 364 Italians were using at least one 
inappropriate medication. Their findings indicated that irrespective of possible confounds, the 
use o f inappropriate drugs is associated with impaired physical performance and that the 
association became stronger with the increasing number of inappropriate medications used.
A study conducted in the United States looked at both prescribed and over the counter 
medications and their subsequent effect on the activities of daily living (ADE) in a population of 
community dwelling older women (Magaziner, Cadigan, Fedder, & Hebei, 1989). These 
researchers examined 609 women in two interviews that were held one year apart in Baltimore, 
Maryland. After controlling for variables such as age, education, physical health, number of 
chronic conditions and baseline functional status, they found that prescription medication use to 
be associated with functional declines in ability to perform both their physical (eating, dressing.
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bathing, etc.) and instrumental (using the phone, walking, shopping, etc.) ADLs. The same study 
demonstrated that over the counter medicine only had a negative effect on physical ADL.
As we have seen, medications can cause a decrease in physical functioning and in 
cognition, and can cause side effects that lead to falls and fractures. Therefore, it should not be 
surprising that decreases in the ability to operate a motor vehicle have also been found in older 
drivers who are on medications. An increase risk of motor vehicle accidents in the elderly 
population has been found to be associated with antidepressant use (Ray, Fought, & Decker, 
1992) and benzodiazepine use (Hemmelgarn, Suissa, Huang, Boivin, & Pinard, 1997; Ray, 
Fought, & Decker, 1992). One population-based case-control study from Alabama (McGwin, 
Sims, Pulley & Roseman, 2000) found that the use of benzodiazepines was associated with an 
increased risk of at-fault involvement in crashes.
After reviewing the literature, it is clear that medications can cause a number of negative 
effects within the population over the age o f 65. It is important for the health care system and 
the country as whole to minimize such harmful effects. Many methods are currently be 
attempted by researchers and governments in order to discover new methods and develop 
systems that reduce adverse effects. One proven way to reduce adverse drug effects is to have all 
medications periodically reviewed by a qualified health professional.
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Medication Reviews
Due to the increased probability of adverse reactions caused by medications in the older 
population, medication reviews performed by qualified health professionals are necessary and 
should performed regularly on older individuals receiving multiple medications.
Research has shown that one o f the foremost positive effects of medication reviews is that 
they typically lead to a decrease in the total number o f medications being taken by the elderly 
(Bolton, Tipper & Tasker, 2004; Lenaghan, Holland, & Brooks, 2007; Williams et al. 2004). By 
having their medications reviewed, patients are relieved o f any unnecessary or inappropriate 
medications that may be affecting their well-being. A review article by Chumney and Robinson 
(2006) examined a large number of studies that looked at drug regimen reviews performed by 
pharmacists. Their work found that medication reviews can lead to a number o f positive effects 
including reduced number o f medications, increased adherence, decreased adverse drug 
reactions, and increased quality of life.
One American study (Hanlon et al., 1996) looked at medication reviews performed by 
pharmacists on 208 patients over the age o f 65. All subjects were on 5 or more medications and 
were randomly split into a control group and experimental group. Those in the experimental 
group met with a pharmacist to review their drug regimen while those in the control group where 
treated as per usual. The individuals who received the complete medication review were found 
to experience less adverse drug reactions as well as having fewer inappropriate medications.
Another study specifically looked at the effect o f medication reviews performed by general 
practitioners on their patients over 65 (Bolton, Tipper, & Tasker, 2004). Sixty-four GPs 
participated in the study, each enrolling at least 12 of their patients. Data on the total number of 
medications, number and dosage of selected cardiovascular, and psychotropic medications were
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taken into account. After the patients’ medications were reviewed, it was found that the number 
o f medications was significantly decreased, the dose and number o f benzodiazepines 
significantly decreased, and the number of selective serotonin reuptake inhibitors significantly 
increased.
There are also a number of other reasons for a need of frequent medication reviews among 
older adults. For example, seniors are often serviced by a number o f different health care 
professionals. By having a number of different medication prescribers, inappropriate 
prescriptions and unnecessary therapeutic duplication can easily occur. Additionally, as 
individuals grow older, many may have a number of different chronic conditions. Each separate 
condition can have a need for one or more prescriptions, which eventually leads to 
polypharmacy. As the number o f medications and conditions grow, it is vital to check to make 
sure medications and conditions are not interacting with other medications or diagnoses causing 
adverse reactions. Senior’s health care is also not always given to them in a coordinated manner 
in that no one person is responsible for care. Quite often older people see a wide range of 
different professionals from nurses to pharmacists to health care aides, which can easily lead to 
miscommunications and medication issues.
One segment of these older populations in which medication reviews may be even more 
essential is that o f those receiving home care. Every year in Ontario, the Community Care 
Access Centres provide coordinated access to health and support services to approximately 
500,000 clients, and provides services daily to approximately 185,000 Ontarians in their homes 
(OACCAC, 2007). Since individuals receiving care at home are not in an institutional setting 
with supervision o f doctors, there is an increased chance that their medications will be not be 
reviewed and medication oversight will have occurred for them. Aparasu and Mort (2004)
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found that 7.14% of all community dwelling elderly in the U.S. or 2.30 million people received a 
potentially inappropriate psychotropic medication. This study demonstrates the prevalence of a 
medication issue within the population of elderly living outside o f institutions.
Because of the growing importance o f home care and the medication issues that occur in 
the older population, Meredith et al. (2002) examined the effect o f a medication improvement 
program on medication use in a population of approximately 70 000 home care patients. Patients 
were screened for possible medication issues and those selected to have possible medication 
issues were randomly divided into a usual care group and a usual care with medication 
improvement program group. Medication use improved for 50% of intervention patients and 
38% of control patients, an improvement o f 12 patients per 100. The greatest effect of the 
intervention was for therapeutic duplication, with improvement for 71% of intervention and 24% 
of control patients, an improvement of 47 patients per 100.
After reviewing the literature, one can deduce that medication reviews have a positive 
effect on individuals by reducing the number of medications, reducing the number of 
inappropriate medications, increasing adherence, decreasing adverse drug reactions, as well as 
increasing quality of life. When considering the growth in the numbers o f elderly that is 
occurring within Canada’s population and the potential adverse effects caused by medication 
problems, one should agree that it is vital to study and examine these issues and take a proactive 
approach in order to avoid future troubles. One way to accomplish this proactive approach would 
be to better understand medication reviews and their effect on health status and medication use 
among older adults. By doing such, we should be able to better understand their health issues 
related to medications as well as to better understand the issues of medication reviews and 
inappropriate medication use.
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Routinely Collected Clinical Data
Routinely collected clinical data refers to data that is routinely collected by a facility or an 
organization. This data is specifically collected in order to aid clinical decision-making and to 
assist in the administration o f the process or the organization. The main purpose of routinely 
collected clinical data is to support care planning and not for the purposes of research. However, 
when collected in a reliable manner, the data can have significant potential for use in research.
The Minimum Data Set (MDS)
One widely used type of routinely collected clinical data is the MDS, which is the 
assessment component of the Resident Assessment Instrument (RAI). The RAl and MDS were 
developed by interRAI, a collaborative network of researchers from over 20 countries. A 
number of different instruments or tools based on a common core set of items have been 
developed by this network in order to be used by different populations (i.e., long term care, home 
care, mental health) all the while working together to form an integrated health information 
system (interRAI, 2008).
The RAI instruments were developed with a number of applications in mind. The main 
objective was to develop a tool to provide all-inclusive assessment as the basis for care planning 
(interRAI, 2008). This objective was not to automate the care planning process but to assist in 
performing it. A second aim of the RAI instruments is using assessment information to 
contribute to the area of case mix funding (interRAI, 2008). Case mix is a system that classifies 
individuals into groups that are uniform in their use of resources (interRAI, 2008)..
Governments can utilize case mix in order to assist them in allocating their resources to the 
people in need in an evidence based way. A third objective of the interRAI assessment systems is
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outcome measurement (interRAE 2008). These tools can be used to measure both the status and 
the outcomes of individuals or groups of people. Within each separate tool are scales and indices 
that can provide insight to an individual’s cuirent status. The fourth application is to provide 
quality indicators to: (a) the organizations providing care in order to improve their services; (b) 
the government to monitor care; and (c) the public for reporting purposes (interRAI, 2008).
For the current study, the RAI-HC tool will be utilized. This tool employs a Minimum Data 
Set form as its assessment component. It is a standardized set of 120 items organized into 23 
categories. The different categories gather information on function, health, social support and 
service use of the individuals (Morris et al, 1999).
In terms o f reliability, the RAI-HC tool has been proven to be a reliable and valid tool by a 
number of different researchers (Kwan, Chi, Lam, Lam & Chou, 2000; Landi et al., 2000; Morris 
et al., 1997). This assessment tool is currently being used in many countries outside of Canada 
including the U.S., Italy, Switzerland, Japan, and Australia.
In 2002, the province o f Ontario mandated that the Resident Assessment Instrument -  
Home Care (RAI-HC) be used to serve this organizational purpose for all home care clients 
expected to be utilizing service for 60 days or more. Thus, since 2002, every individual who has 
received home care in the province has had a standardized set of information taken on him or her 
with the primary goal being assessment. From the assessment, the following components are 
derived:
• Client Assessment Protocols
• Outcome Measures
• Method for Assigning Priority Levels
• Quality Indicators
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Client Assessment Protocols (CAPs)
CAPs are designed to assist the assessor in interpreting all of the client’s information 
recorded on the MDS-HC (Morris et al, 1999). These Assessment Protocols are not meant to 
automate the care planning; rather they are intended to point out key issues or potential trouble 
areas. When a CAP is activated or has a positive result, the clinician can focus on the area and 
explore possible ways to intervene. Each Assessment Protocol has been designed by a number 
of researchers and validated through clinical focus groups and studies (Morris et al, 1999).
Outcome Measures
The current status and outcomes of individuals are also measured by using the items found 
on the MDS-HC. By systematically combining different items, various scales and indices are 
formed indicating the current status o f the client. These measures can be compared from initial 
assessment and follow up (usually 6 months later) to determine changes in the different domains. 
The outcome measures explored in the current study include the Cognitive Performance Scale, 
the Depression Rating Scale, the Activities of Daily Living Hierarchy, and the Instrumental 
Activities o f Daily Living Sum.
Method for Assigning Priority Levels (MAPLe)
The MAPLe is a scale designed to use MDS-HC items to determine home care clients’ 
priority levels for institutionalization and caregiver burn-out (Hirdes, Poss, & Curtin-Telegdi, 
2008). Clients who score high on this scale typically trigger the nursing home CAP and have 
ADL impairment, cognitive impairment, and behavioural problems (Hirdes, Poss, & Curtin- 
Telegdi, 2008). Clients with low priority levels have no such issues and can be considered
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functional and self-reliant (Hirdes, Poss, & Curtin-Telegdi, 2008).
Quality Indicators
In order to improve the overall quality of care provided within homecare, inter-RAl 
developed home care quality indicators (HCQls) for the MDS-HC. This effort lead to a set o f 22 
HCQls based on the MDS-HC data (Dalby, Hires, & Fries, 2005). This set is a mixture of 
prevalence measures and incidence measures. When HCQls have a high rate within a 
community it is indicative of poorer service provision for that measure. These HCQls can be 
used to support a variety of quality functions including internal quality management initiatives, 
external quality comparisons to other home care providers/communities and public report cards 
(Hirdes et al., 2004).
Implications for Research
The MDS can be a valuable tool for gathering evidence, profiling clients that have chronic 
illnesses, and to find how those illnesses affect different aspects o f their lives. Once the profile 
of individuals with certain health issues is known, health promotion interventions can be used to 
target those individuals.
Harrison et al. (2006) conducted a study that looked at use of MDS data to determine the 
extent to which nursing interventions provided during hospitalization are associated with 
patients' therapeutic self-care and functional health outcomes. The results indicated that 
particular interventions aimed at promoting exercise, positioning and self-care assistance 
predicted functional status outcome. They concluded that nurses could use the MDS data on 
patient outcomes to assess the effectiveness of their interventions.
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Gruneir, Smith, Hirdes, and Cameron (2005) performed a study of health o f the elderly 
utilizing MDS data. Their goal was to use the MDS to examine the prevalence of depression; its 
recognition and its treatment in continuing care patients with advanced illness. The study found 
that patients with advanced illness were more than twice as likely to be depressed than other 
patients and were also less likely to be receiving antidepressants. The MDS data also revealed 
that the cancer patients in the study received better end of life care than others.
Current Study
Existing literature has clearly demonstrated the large number of possible and preventable 
deleterious effects caused by medication use. Research has also clearly demonstrated that having 
a medication regime reviewed by a qualified health professional can reduce number of 
medications and the number of inappropriate medications, increase adherence, decrease adverse 
drug reactions, and increased quality of life. To explore these issues further, data from Ontario 
home care patients will be explored using information collected with the RAI-HC assessment 
tool. This current exploration into the RAI-HC data aims to investigate provincial prevalence of 
medication oversight, differences between those with and without medication reviews using 
traditional statistical analyses and the effect o f medication oversight on a number o f outcome 
measures utilizing mixed linear analyses.
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Methodology
This thesis used data collected by the 14 Community Care Access Centres across Ontario 
using the MDS-HC assessment tool as mandated by the provincial government. All data comes 
from clients of the CCACs who are either receiving home care, those recently released from 
acute care and those who have been waitlisted for long term care. The dataset used for this study 
was drawn from the February 2008 provincial data cut and was electronically stored in Waterloo, 
Ontario, and accessed remotely from Thunder Bay.
Sample
Secondary data analyses were conducted using 212,756 first time CCAC client 
assessments that were performed with the RAI-HC. O f those clients, 92 811 had a second 
assessment. The original data set was reduced by the following means:
1. All clients who had only the initial assessment were removed leaving only those 
who had a second assessment to be analyzed. This was done to ensure that 
persons were utilizing home care for more than 6 months and had a chance to 
have their medications reviewed during that time.
2. All clients who were on no medications or 1 medication were removed from the 
dataset. This was done to ensure that only the people who were in need of 
medication reviews were used in the study. This data reduction is also performed 
by interRAI when calculating the Home Care Quality Indicator that monitors 
medication oversight.
3. All clients under the age of 65 were removed from the dataset. This was 
performed in order to only analyze the population of interest, older adults o f  the 
age of 65 or older.
After performing the above reductions, the data set contained 76 810 clients. In this 
sample of assessments, the average age of the subjects was 81.44 years and range was from 65 to
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106 years. Females made up 66.85% of this sample (51 223). Table 1 presents the frequency of 
clients bv CCAC.
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Table 1






Erie St. Clair 4239
Hamilton Niagara 12 537
Mississauga Halton 4507
North East 4296







Medication oversight was tlie key variable of interest. Those clients who had all o f their 
medications reviewed by a health professional in the past 180 days were scored with a 0, and no 
medication oversight occurred for them. Those persons who had not had a health professional 
review their medication regime in the past 180 days were scored with a 1, with medication
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oversight occurring in such persons. This item is found on both the initial assessment at time 1 
and on the follow-up assessment at time 2.
An average medication oversight score was created for each CCAC at both time 1 and 
time 2 by taking the number of patients with medication oversight within each CCAC and 
dividing it by the total number of patients within each CCAC. The CCAC means were used to 
create a centered score for medication oversight at both time 1 and time 2. A centered score was 
created for each client for both time assessments.
A third variable called “drug category” was created for the number o f medications they 
consumed in the last week. The variable had 3 categories: those who consumed two to five 
medications, those who consumed five to eight medications, and those who consumed nine or 
more medications.
All outcome measures and Client Assessment Protocols are based on MDS-HC items that 
have been shown to have an average inter-rater reliability o f .85 (Morris et al., 1999). Six 
outcome measures were used as dependent variables:
1. Cognitive Performance Scale
2. Depression Rating Scale
3. MAPLe
4. CHESS
5. Activities o f Daily Living Hierarchy
6. Instrumental Activities of Daily Living Sum
The Cognitive Performance Scale (CPS) has been shown to accurately discriminate level 
of cognition among institutionalize populations (Harmaier et al., 1995). It makes use o f an 
algorithm that combines information on memory impairment, level of consciousness, and 
executive functioning. The CPS has shown to be highly correlated {r = -.863, p  < .001;
Hartmaier et al., 1995) with the Mini Mental State Exam in nursing home residents. This scale
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ranges from 0-6 with 0 meaning the client is cognitively intact and 6 signifying severe 
impairment (interRAI, 2008).
The Depression Rating Scale (DRS) is a summation of 7 items on the MDS-HC. This 
scale is highly correlated with the Hamilton Depression Scale (r = .70) and the Cornell Scale (r = 
.69) and was developed using samples o f older adults living in nursing homes (Burrows, Moris, 
Simon, Hirdes, & Phillips, 2000). This scale ranges from 0, no symptoms present, to 2, daily 
occurrence of depressive symptoms (interRAI, 2008).
The Activities of Daily Living Hierarchy Scale uses 4 items to assess the clients’ level of 
functioning in activities o f daily living including eating ability, personal hygiene, ability to toilet 
oneself, and walking/locomotion. Internal consistency of .90 has been reported in past research 
(Morris et al., 1999). Th ADL Hier Scale ranges from 0, meaning the client is independent, to 6, 
signifying a total dependence for their activities of daily living (interRAI, 2008).
The Method for Assigning Priority Levels (MAPLe) is a psychometrically sound 
décision-support tool that is used to inform choices related to the allocation o f home care 
resources and prioritization of clients needing community or facility-based services. This 
algorithm has been shown to be a strong predictor of nursing home placement, caregiver distress 
and for being rated as requiring alternative placement to improve outlook (Hirdes, Poss, & 
Curtin-Telegdi, 2008), and has been validated with data from four provinces and five other 
countries. The MAPLe ranges from low which is represented by a score o f 1, to high which is 
scored with a 5 (Hirdes, Poss, & Curtin-Telegdi, 2008).
The Changes in Health, End-stage disease and Symptoms and Signs (CHESS) scale is a 
composite measure made up from MDS-HC items. It examines changes in health, end-stage 
disease and symptoms and signs of medical problems. It has been proven to be a strong
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predictor o f mortality {p < . 0001; Hirdes, Frijters, & Teare, 2003) among older adults in chronic 
care facilities. Further research is needed to validate this tool in home care settings. This scale is 
a 6-point scale (Hirdes, Frijters, & Teare, 2003) with scores ranging between 0 (meaning no 
instability) to 5 (for the highest level of instability).
The Client Assessment Protocols (CAPs) have been designed specifically to aid in further 
assessment and individualized care planning for clients who have problematic trigger conditions. 
All CAPs have been developed by teams of clinicians and researchers and have been validated 
through focus groups and research studies (Morris et al., 1999). The CAPs are scored in a binary 
format (not trigger = 0, triggered = 1). Complete descriptions of all 30 of the CAPs as well as 
their triggering rules can be found within the RAI-HC Handbook (Morris et al., 1999).
Analvses
Once connected to the computers at Waterloo, SAS 9.1 was used to perform the 
secondary analyses of the anonymized data set.
The t-tests and Chi-squared tests were used to compare the frequencies on the outcome 
measures and CAPs between those with a recent medication review at the second assessment 
(time 2) and those without.
Mixed Linear Analysis (MLA) was chosen to analyze the outcome measures. MLA is 
used for research designs where the data for participants Is organized at more than one level. For 
this study, participants are clients with the CCAC system within the province of Ontario.
Clearly, demographic makeup, staffing ratios, availability of family physicians, environmental 
hazards, etc., vary from one CCAC to the next. Therefore, for the MDS-HC data, MLA analyses
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must be used in order to account for this clustering of participants. Only two levels were used in 
the models, individuals and CCACs.
Separate MLA analyses were computed for each outcome measure. Each analysis was 
sequential and included a null model and tliree further models that increased in complexity. The 
null model included CCACs as a random intercept with no fixed effects. A significant intercept 
provides evidence that CCACs differ significantly on the dependent variable. In model 1, 
centered medication oversight at time 2 was added as a fixed effect to determine its fixed 
relationship with the outcome measure with CCAC controlled. Centering in this and subsequent 
models was with respect to the CCAC mean. Model 2 included centered medication oversight at 
time 2 as both fixed and random variables. This model tests the viability of centered medication 
oversight as a random individual difference measure. Failures of convergence or identification 
suggest that centered medication oversight is not viable as a random individual difference 
measure with the data set analyzed. Consequently, it was omitted from the list of random 
variables in model 3. Model 3 added additional variables as fixed effects. These include the 
categorical variable of number of drugs taken, age, gender, living status (alone or not alone), 
CCAC mean oversight at time 2, and centered medication oversight at time 1. Also included as 
fixed effects in model 3 were interactions between the centered medication oversight at time 2 
with (a) drug categories and (b) CCAC mean medication oversight at time 2.
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Results
The prevalence rate at the first assessment was 2.67% (n = 2047) and at second 
assessment the medication oversight prevalence rate was 2.03% (n = ! 556).
Due to the way that the number of medications is measured on the MDS-HC, the true 
mean for number of medications cannot be calculated. The range on the MDS-HC for the 
number of medications currently taken by a client is from zero to nine plus. Therefore, all clients 
who are taking 9 or more medications are grouped into a single category. The frequency for 
each of the drug categories at time 2 is shown in figure 3. Of the clients, 46.41% (35 650) 
received nine or more medications while 25,82% (19 066) received five or less.
Figure 3. Frequency o f  People by Number o f  Medications
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The results for Chi-square tests for the CAPs comparing the frequencies of those with 
medication oversight at time 2 to those with no medication oversight at time 2 can be found in 
table 2. O f the 29 CAPs analyzed, 17 were found to differ significantly between the two groups 
at the .05 level. The CAPS that differed significantly at the p  < .05 level in order o f decreasing 
Chi square values were Adherence, Environmental Assessment, Brittle Supports, Depression and 
Anxiety, Immunization and Screening, Behaviour, Cognition, Alcohol Dependence, Falls, 
Dehydration, Skin and Foot Conditions, Communication, Oral Health, Pressure Ulcers, and 
Reduction of Formal Services. Also included in table 2 is the percentage of each population that 
triggered each individual cap. O f all the prevalence rates for the CAPs, only the Reduction of 
Formal Services CAP had a higher triggered prevalence rate for those who had received a 
medication review in the past 180 days. All other CAPs that had a significant difference 
between the two groups resulted in a higher triggered prevalence rate for those who had 
medication oversight.
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Table 2
Chi-square tests for Client Assessment Protocols (CAPS)








Activities o f Daily Living /
Rehabilitation Potential 0.1505 0.6981 39.05 38.56
Instrumental Activities of
Daily Living 0.0186 0.8916 80.07 80.21
Health Promotion 0.1778 0.6733 55.76 56.30
Institutional Risk 0.6913 0.4057 17.95 18.77
Commimication Disorders 8.8685 0.0029 56.63 60.41
Visual Function 2.2652 0.1323 30.30 32.07
Alcohol Dependence 13.5892 0.0002 1.12 2.12
Cognition 14.7632 0.0001 49.00 53.92
Behaviour 28.9973 <0001 9.61 13.69
Depression and Anxiety 35.7031 <.0001 23.22 29.69
Elder Abuse 0.0276 0.8680 0.73 0.77
Social Function 22.8655 <0001 20.79 25.77
Cardio-Respiratory 0.9994 0.3174 33.30 34.51
Dehydration 12.6465 0.0004 3.42 5.08
Falls 13.5050 0.0002 47.87 52.57
Nutrition 0.2047 0.6510 20.39 19.92
Oral Health 6.0401 0.0140 14.73 16.97
Pain 0.2055 0.6503 63.22 62.66
Pressure Ulcers 5.5191 0.0188 18.73 21.08
Skin and Foot Conditions 13.3458 0.0003 31.26 35.60
Adherence 115.5495 <.0001 6.16 12.85
Brittle Supports 35.7706 <0001 18.92 24.94
Palliative Cai'e 1.9772 0.1597 1.31 0.90
Immunization and Screening 32.1324 <0001 88.59 93.19
Psychotropic Drugs 0.0499 0.8232 33.17 32.90
Reduction of Formal
Services 5.1494 0.0233 14.65 12.60
Environmental Assessment 88.5006 <0001 5.33 10.80
Bowel Management 4.6302 0.0314 16.28 18.32
Urine Incontinence 2.0704 0.1502 41.95 43.77
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Table 3 displays the result for the t-tests between the six outcome measures comparing 
the means o f those with medication oversight to those with no medication oversight. All but 
lADL Sum were found to be significantly different at the .05 level.
Table 3
T-tests fo r Outcome Measures
Average Score of Average Score of
Persons with Persons with
t- Medication Review Medication
’Variable value P Oversight
ADL Hierarchy -1.47 0.1411 0.746 (SD = 1.254) 0.794 (SD = 1.310)
CHESS -3.48 0.0005 1.152 (S D = 1.049) 1.246 (SD -  1.115)
Cognition Performance Scale -3.12 0.0018 1.195 (S D = 1.342) 1.302 (SD -  1.358)
Depression Rating Scale -6.44 <.0001 0.967 (SD -  1.770) 1.261 (SD -  2.043)
MAPLe -5.36 <.0001 2.966 (SD = 1.280) 3.142 (SD -  1.285)
lADL Sum 1.64 0.1018 12.13 ( S D - 5.769) 11.89 ( S D - 5.694)
Note. SD = Standard Deviation.
Table 4 shows the percentage of clients without a medication review for each CCAC at 
both the initial assessment (Time 1 ) and the follow up assessment (Time 2). The CCAC with the 
highest prevalence o f medication oversight at both times was South West (Time 1 = 4.82%,
Time 2 -  3.69%). The Central CCAC scored the lowest with at both assessment times. All 
CCACs had lower prevalence rates at the time o f the clients’ second assessment. The prevalence 
rate across all CCACs was 2.61% for time 1 and 2.01% for time 2 (t[13]= 7.96, p<.001).













Central East 3.32% 2.53%
Central West 1.67% 1.48%
Champlain 2.28% 1.60%
Erie St. Clair 2.42% 2.31%
Hamilton Niagara 2.83% 2.42%
Mississauga Halton 1.67% 1.11%
North East 3.26% 2.54%
North Simcoe Muskoka 2.37% 1.42%
North West 3.06% 2.14%
South East 2.88% 2.13%
South West 4.82% 3.69%
Toronto Central 2.35% 1.67%
Waterloo Wellington 1.97% 1.18%
A correlation matrix between the medication oversight items (both Time 1 and Time 2), 
the drug category variable and the 6 health outcome variables can be found in Table 5. 
Medication oversight at time 1 (M O-Tl) correlates with the Time 2 medication oversight (MO- 
T2) with r = .540. The highest correlation was found between the MAPLe and CPS scores witli 
r  = .681. The Values are low enough that multicollinearity is not expected to be a significant 
threat to the validity of the regression analyses that follow.
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Table 5














MO-Tl 1.00 .540 .028 .018 .013 .022 .006 .008 -.004
M 0-T2 1.00 .026 .019 .010 .024 .008 .013 -.005
Drug 1.00 .047 .106 -.041 .015 -.104 -.005
Category
MAPLe 1.00 .681 .188 .380 .231 .649
CPS 1.00 .139 .401 .152 .571
DRS 1.00 .098 .196 .098





Results o f the mixed linear analysis are shown in tables 6 through to 17, with two tables 
for each outcome measure. Each model lists the -2 Res Log Liklihood for the model, the random 
effects and the fixed effects results. For each null model, the effect of the CCAC grouping was 
found to be significant. The highest intraclass correlation for the null model was found in the 
Instrumental Activities of Daily Living Sum outcome measure (0.0248) and the lowest intraclass 
correlation was found in the Depression Rating Scale (0.00183).
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In table 6, the MLA results for the Null Model and Model 1 for the MAPLe are 
displayed. For the Null model, the Intercept and Residual estimates were found to be significant 
with 1.25% of variance due to the CCAC groupings. In model 1, the centered medication 
oversight at time 2 (Cen MO T2) was found to have a significant linear relationship with the 
MAPLe outcome scores. Model 2 did not converge for the MAPLe.
Table 6
Mixed Linear Analyses Results fo r  MAPLe: Null Model and Model 1
Null Model
Estimate SE Z Value P rZ
Random
Effects Intercept 0.02048 0.008138 2.52 0.0059
Residual 1.6225 0.008321 195.00 <.0001
Intraclass Correlation = 0.0125
-2 Res Log Likelihood 252735.7
Added Fixed Variable to N ull Model: Centered Medication Oversight
Model 1 A t Time 2
Estimate SE Z value PrZ
Random
Effects Intercept 0.02048 0.008138 2.52 0.0059
Residual 1.6218 0.008317 195.00 <.0001
Estimate SE T value P rT
Fixed
effects Intercept 2.9626 0.03860 76.74 <.0001
Cen MO T2 0.1929 .03271 5.90 <.0001
-2 Res Log Likelihood = 252706.0
Note. Cen MO T2 = Centered medication oversight at time 2.
In Table 7, the results for Model 3 for the MAPLe outcome are given. Significant 
predictors of the MAPLe score from this model included the number of drugs categorical
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variable (Drug Category), social living circumstance (Alone), gender, age, and the centered 
medication oversight at time 1 variable.
Table 7




Estimate SE Z value P rZ
Intercept 0.01298 0.005432 2.39 0.0084
Residual 1.4998 0.007704 194.68 <.0001
Estimate SE T value P rT
Intercept
Centered MO Time
1.4946 0.1064 14.05 <.0001
2 -0.03637 0.1251 -0.29 0.7713
Drug Category 
Centered MO T2 *
0.09932 0.006135 16.19 <.0001
Drug Category 0.08746 0.04077 2.15 0.0319
Alone 0.6680 0.009659 69.17 <.0001
Gender -0.1376 0.009690 -14.20 <.0001
Age
Centered MO
0.01412 0.000636 22.20 <.0001
Time 1 0.1232 0.03256 3.79 0.0002
CCAC Average 
Cen MO T2 *
-2.8167 4.3916 -0.64 0.5333
CCAC Average 0.1250 3.9966 0.03 0.9749
Random
Effects
-2 Res Log Likelihood -  245986.5
Note. Cen MO T2 = Centered medication oversight at time 2, Drug Cateregory = categorical 
variable representing the number of drugs client is taking, Alone = social living circumstance for 
client, CCAC Average = average medication oversight at time 2 for the CCAC to which the 
client belongs.
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In table 8, the MLA results of the Null Model and Model 1 for the CPS are displayed.
For the Null model, the Intercept and Residual estimates were found to be significant with 1.08% 
of variance due to the CCAC groupings. In model 1, the centered medication oversight at time 2 
(Cen MO T2) was found to have a significant linear relationship with the CPS scores. Model 2 
did not converge for the CPS.
Table 8
Mixed Linear Analyses Results fo r  Cognitive Performance Scale: Null Model and Model 1
Null Model Estimate SE Z Value PrZ
Random
Effects Intercept 0.01940 0.007779 2.49 0.0063
Residual 1.7833 0.009146 194.98 <.0001
Intraclass Correlation = 0.0108
-2 Res Log Likelihood = 259873.0
Added Fixed Variable to N ull Model: Centered Medication Oversight
Model 1 A t Time 2
Estimate SE Z value P rZ
Random
Effects Intercept 0.01940 0.007770 2.49 0.0063
Residual 1.7831 0.009145 194.98 <.0001
Estimate SE T value P rT
Fixed effects Intercept 1.1901 .03763 31.63 <.0001
Cen MO T2 0.1191 0.03430 3.47 0.0005
-2 Res Log Likelihood = 259865.9
Note. Cen MO T2 = Centered medication oversight at time 2.
Exploring Medication Oversight 48
In Table 9. the results for Model 3 for the CPS outcome are given. Significant predictors 
of the Cognitive Performance Scale scores from this model included the number of drugs 
categorical variable (Drug Category), social living circumstance (Alone), gender, age, and the 
centered medication oversight at time 1 variable.
Table 9






Estimate SE Z value P rZ
Intercept 0.01478 0.006160 2.40 0.0082
Residual 1.6592 0.008524 194.66 <.0001
Estimate SE T value P rT
Intercept
Centered MO Time
-0.5642 0.1131 -4.99 0.0003
2 -0.3172 0.1316 -0.24 0.8085
Drug Category 
Centered MO T2 *
0.2093 0.006454 32.43 <.0001
Drug Categoiy 0.07054 0.04288 1.65 0.0999
Alone 0.6096 0.01016 60.00 <.0001
Gender -0.1280 0.01019 -12.56 <.0001
Age
Centered MO Time
0.01503 0.000669 22.47 <.0001
1 0.1101 0.03425 3.22 0.0013
CCAC Average 
Cen MO T2 *
-0.4281 4.6842 -0.09 0.9287
CCAC Average -2.3802 4.1770 -0.57 0.5688
-2 Res Log Likelihood = 253601.5
Note. Cen MO T2 = Centered medication oversight at time 2, Drug Cateregory = categorical 
variable representing the number of drugs client is taking. Alone = social living circumstance for 
client, CCAC Average = average medication oversight at time 2 for the CCAC to which the 
client belongs.
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Table 10 displays the MLA results of the Null Model, Model 1, and Model 2 for the 
DRS. For the Null model, the Intercept and Residual estimates were found to be significant with 
0.18% of variance due to the CCAC groupings. This intraclass correlation for the DRS was the 
smallest of the six outcomes in these analyses. In model 1, the centered medication oversight at 
time 2 (Cen MO T2) was found to have a significant linear relationship with the DRS scores.
This relationship (t = 6.57) was the strongest of all Model 1 results. For the DRS, Model 2 did 
converge after adding the centered medication oversight at time 2 as a random variable.
However, it resulted in a non-significant random effect.
Exploring Medication Oversight 50
Table 10
Mixed Linear Analyses Results for Depression Rating Scale: Null Model, Model 1 and Model 2
Null Model Estimate SE Z Value P rZ
Random
Effects Intercept 0.005772 0.002529 228 0.0112
Residual 3.1512 0.01617 194.92 <dW01
Intraclass Correlation = 0.00183
-2 Res Log Likelihood = 302946.2
Added Fixed Variable to Null Model: Centered Medication Oversight
Model 1 At Time 2
Estimate SE Z value P rZ
Random
Effects Intercept 0.005773 0.002529 228 0.0112
Residual 3.1494 0.01616 194.92 <.0001
Estimate SE T value P rT
Fixed
effects Intercept (E9610 0.02154 44.62 <0001
Cen MO T2 0.2999 0.04561 &57 <0001
-2 Res Log Likelihood = 302907J
Added Random Variable to Model 1: Centered Medication Oversight
Model 2 At Time 2
Estimate SE Z value P rZ
Random
Effects Intercept 0.005773 0.002529 228 0.0112
Cen MO 12 0.03441 (L02538 L36 0.0876
Residual 3T488 0.0I6I6 194.90 <.0001
Estimate SE T value P rT
Fixed
effects Intercept 0.9610 0.02154 44.62 <TW01
Cen MO T2 0.2563 0.07123 160 0TW32
-2 Res Log Likelihood = 302900.5
Note. Cen MO T2 = Centered medication oversight at time 2.
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In Table 11, the results for Model 3 for the DRS outcome are given. Significant 
predictors of the Depression Rating Scale scores included the number of drugs categorical 
variable (Drug Category), social living circumstance (Alone), gender, age, and the centered 
medication oversight at time 1 variable.
Table 11
Mixed Linear Analyses Results for Depression Rating Scale: Model 3
Model 3
Estimate SE Z value PrZ
Intercept 0.006010 0.002731 22 0 0.0139
Centered MO Time 2 0.02702 0.2574 1.05 0.1469
Residual 3 .II2 I 101599 194.58 <0001
Estimate SE T value P rT
Intercept 2.4340 0.1020 2187 <.0001
Centered MO Time 2 0.03902 12286 117 0.8644
Drug Category 
Centered MO T2 *
-0.07456 0.008840 -8.43 <.0001
Drug Category -0.04926 0.05888 -0.84 0.4028
Alone 0.2026 0.01391 14.56 <.0001
Gender 0T586 0.01396 11.36 <.0001
Age -0.02152 1000917 -23.48 <.0001
Centered MO Time I 0.I37I 0.04701 2.92 0.0035
CCAC Average 
Cen MO T2 * CCAC
0.4983 3.0875 0.16 0.8745
Average








Note. Cen MO T2 = Centered medication oversight at time 2, Drug Cateregory = categorical 
variable representing the number of drugs client is taking. Alone = social living circumstance for 
client, CCAC Average = average medication oversight at time 2 for the CCAC to which the 
client belongs.
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Table 12 displays the MLA results of the Null Model and Model 1 for the ADL 
Hierarchy item. For the Null model, the Intercept and Residual estimates were found to be 
significant with 1.84% of variance due to the CCAC groupings. In model I, the centered 
medication oversight at time 2 (Cen MO T2) was found to have a significant linear relationship 
with the ADL Hier scores. Model 2 converged but the random effect o f the centered medication 
oversight at time 2 was found to be non significant.
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Table 12
Mixed Linear Analyses Results fo r  Activities o f  Daily Living Hierarchy Scale: Null Model and
Model I
Null Model Estimate SE Z Value PrZ
Random
Effects Intercept 0.02904 0.01150 253 0.0058
Residual 1.5477 0.007938 194.97 <0001
Intraclass Correlation = 0.0184
-2 Res Log Likelihood ^ 249073.1
Added Fixed Variable to Null Model: Centered Medication Oversight
Model 1 At Time 2
Estimate SE Z value PrZ
Random
Effects Intercept 0.02904 0.01150 2.53 0.0058
Residual 1.5476 0.007938 194.97 <0001
Estimate SE T value P rT
Fixed effects Intercept 02552 0.04583 16.48 <0001
Cen MO T2 0.0916 0.03195 2 8 7 0.0041
-2 Res Log Likelihood ^ 249070.0
Added Random Variable to Model 1: Centered Medication Oversight
Model 2 At Time 2
Estimate SE Z value PrZ
Random
Effects Intercept 0.02904 (FOI 150 2.53 0.0058
Cen MO T2 0.01363 0.01764 0.77 0.2198
Residual 1.5474 0.007938 19423 <2001
Estimate SE T value P rT
Fixed effects Intercept 02552 0.04583 16.48 <0001
Cen MO T2 0.09031 0.04727 I.9I 0.0783
-2 Res Log Likelihood 249069T
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In Table 13, the results for Model 3 for the ADL Hier outcome are given. Significant 
predictors o f the ADL Hier scores included social living circumstance (Alone), gender, age, the 
centered medication oversight at time I variable and the CCAC time 2 average medication 
oversight score.
Table 13
Mixed Linear Analyses Results fo r  Activities o f  Daily Living Hierarchy Scale: Model 3
Model 3
Estimate SE Z value P rZ
Intercept (FOI 159 0.004947 22 4 0.0095
Centered MO Time 2 0.0I98I 0.01858 1.07 0.1431
Residual 1.4567 0.007485 194.62 <.0001
Estimate SE T value P rT
Intercept (F3483 0.I0I8 242 0.0051
Centered MO Time 2 (F03927 0.1709 (F23 0.8183
Drug Category (F003957 0.006048 265 0.5130
Centered MO T2 *
Drug Category 0.04624 0.04026 1.15 0.2507
Alone (F5969 0.009521 6269 <.0001
Gender -0.1384 0.009552 -14.49 <.0001
Age (F005973 0.000627 923 <.0001
Centered MO Time 1 0.07631 0.03215 237 0.0176
CCAC Average -12.4748 4.1540 -3.00 0.0110
Cen MO T2 * CCAC
Average -28640 6.8659 -0.42 0.6766





Note. Cen MO T2 = Centered medication oversight at time 2, Drug Cateregory -  categorical 
variable representing the number of drugs client is taking. Alone = social living circumstance for 
client, CCAC Average = average medication oversight at time 2 for the CCAC to which the 
client belongs.
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Table 14 displays the MLA results of the Null Model, Model 1, and Model 2 for the 
CHESS outcome item. For the Null model, the Intercept and Residual estimates were found to 
be significant with 1.14% of variance due to the CCAC groupings. In model I, tlie centered 
medication oversight at time 2 (Cen MO T2) was found to have a significant linear relationship 
with the CHESS scores. For the CHESS, Model 2 did converge after including the centered 
medication oversight at time 2 as a random variable and the random effects were found to be non 
significant.
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Table 14
Mixed Linear Analyses Results fo r  CHESS: Null Model, Model 1, and Model 2
Null Model Estimate SE Z Value PrZ
Random
Effects Intercept 0.01257 0.005006 2.51 0.0060
Residual 1.0937 0.005609 194.97 <0001
Intraclass Correlation = 0.0114
-2 Res Log Likelihood 22267132
Added Fixed Variable to Null Model: Centered Medication Oversight
Model 1 A t Time 2
Estimate SE Z value P rZ
Random
Effects Intercept 0.01257 0.005006 2.51 0.0060
Residual 1.0936 0.005609 194.97 <0001
Estimate SE T value P rT
Fixed effects Intercept 1.1553 0.03027 38.17 <0001
Cen MO T2 0.08281 0.02687 3.08 0.0021
-2 Res Log Likelihood 222667T
Added Random Variable to Model 1: Centered Medication Oversight
Model 2 A t Time 2
Estimate SE Z value PrZ
Random
Effects Intercept 0.01257 0.005006 2.51 0.0060
Cen MO T2 0.01709 0.01152 1.48 0.0690
Residual 1.0933 0.005608 194.96 <0001
Estimate SE T value P rT
Fixed effects Intercept 1.1553 0.03027 38.17 <0001
Cen MO T2 0.06626 0.046445 1.43 0.1773
-2 Res Log Likelihood 22265732
Note. Cen MO T2 = Centered medication oversight at time 2.
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In Table 15, the results for Model 3 for the CHESS outcome item are displayed. The 
random effect of the centered medication oversight was found to be non significant. Significant 
predictors of the CHESS scores included the number of drugs categorical variable (Drug 
Category), social living circumstance (Alone), gender, and age.
Table 15






Estimate SE Z value PrZ
Intercept 0.01188 0.004921 24 2 0.0079
Centered MO Time 2 0.01783 0.01260 1.42 0.0785
Residual 1.0818 0.005558 194.64 <.0001
Estimate SE T value PrT
Intercept 1.3707 0.09872 1188 <.0001
Cen MO Time 2 0.01460 0.1541 0.09 0.9245
Drug Category -0.1317 0.005211 -25.28 <.0001
Centered MO T2 *
Drug Category 0.002501 0.03473 0.07 03426
Alone 0.05530 0.008205 6.74 <.0001
Gender -0.09183 0.008231 -11.16 <.0001
Age 0.001070 0.000540 L98 0.0477
Centered MO Time I 0.008788 0.02772 032 0.7513
CCAC Average 2.0503 4.1934 0A9 0.6337
Cen MO T2 * CCAC
Average 3.2982 6J029 032 03008
-2 Res Log Likelihood = 221173.4
Note. Cen MO T2 = Centered medication oversight at time 2, Drug Cateregory = categorical 
variable representing the number of drugs client is taking. Alone = social living circumstance for 
client, CCAC Average = average medication oversight at time 2 for the CCAC to which the 
client belongs.
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In Table 16, the MLA results of the Null Model and Model 1 for the lAOL Sum item are 
given. For the Null model, the Intercept and Residual estimates were found to be significant.
The intraclass correlation indicates that 2.48% of variance is due to the CCAC groupings. In 
model I, the centered medication oversight at time 2 (Cen MO T2) was found to have a 
significant linear relationship with the ADL Hier scores. Model 2 did converge for this outcome 
but the random effect of the Cen MO T2 was found to be of non significance.
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Table 16
Mixed Linear Analyses Results fo r  Instrumental Activities o f  Daily Living Sum: Null Model and
Model I


















Added Fixed Variable to Null Model: Centered Medication Oversight 
Model 1 At Time 2
Estimate SE Z value PrZ
Random
Effects Intercept 0.8319 0.3271 2 3 4 0.0055
Residual 32.7029 0T678 194.92 <.0001
Estimate SE T value P rT
Fixed effects Intercept 12.0961 0.2449 4939 <.0001
Cen MO T2 -0.04766 0.1470 -032 0.7457
-2 Res Log Likelihood = 480825.9
Added Random Variable to Model 1: Centered Medication Oversight 
Model 2 At Time 2
Random
Effects
Estimate m Z value PrZ
Intercept 0.8310 03271 2.54 0.0055
Cen MO T2 (102183 0.1180 0.19 04236
Residual 32.7025 03678 194.91 <.0001
Estimate SE T value P rT
Intercept 12.0961 0.2449 4939 <.0001
Cen MO T2 -0.04629 0.1547 -0.30 0.7695
-2 Res Log Likelihood = 480825.9
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Table 17 gives the results for Model 3 for the lADL Sum outcome. Significant predictors 
o f the lADL Sum scores included the number of medications one was taking (Drug Category), 
social living circumstance (Alone), gender, age, the centered medication oversight at time 1 
variable, and the CCAC time 2 average medication oversight score.
Table 17
Mixed Linear Analyses Results for Instrumental Activities o f  Daily Living Sum: Model 3
Model 3
Estimate SE Z value P rZ
Random
Effects Intercept 0.2643 O.lIOl 2.40 03082










Centered MO Time 2 0.08086 0.5243 0.15 0.8774
Drug Category -0.05870 032569 -238 03223
Centered MO T2 * Drug 
Category 0.2180 0.1708 L28 03019
Alone 4.9819 0.04045 123.16 <0001
Gender -0.7750 0.04058 -19.10 <3001
Age 0.I22I 0.002664 45.84 <3001
Centered MO Time I 03212 0.1363 23 6 0.0185
CCAC Average -44.2639 19.7909 -234 0.0451
Cen MO T2 * CCAC
Average -24.1393 16.6309 -1.45 0.1467
-2 Res Log Likelihood = 462730.3
Note. Cen MO T2 = Centered medication oversight at time 2, Drug Cateregory = categorical 
variable representing the number o f drugs client is taking. Alone = social living circumstance for 
client, CCAC Average = average medication oversight at time 2 for the CCAC to which the 
client belongs.
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Discussion
The purpose of this study was to explore medication oversight utilizing MDS-HC data 
through traditional statistical methods and mixed linear analyses. The prevalence rate of 
medication oversight for the dataset was found to be lower tlian 3 percent. Those who did not 
have their medications reviewed differed in many of the Client Assessment Protocols as well as 
in five o f the six health outcome measures. By using mixed linear analyses it was found that 
clustering effects occurred within the MDS-HC data and that missed medication review was a 
significant predictor of some of the variance for each of the health outcome measures.
The prevalence rate at the first assessment was 2.67% (n = 2047) and at second 
assessment the medication oversight prevalence rate was 2.03% (n = 1556). Due to a lack of 
previous research into medication oversights, there are no previously published rates to compare 
this rate to. When looking at the 14 CCACs, prevalence rates varied across province from 1.09% 
in Central to 3.69% in the South West. All CCACs improved their rates at the time of the second 
assessments. This is a positive result, which demonstrates that once a client has entered into the 
CC AC system, the client is more likely to have received a review of their medication regime.
From the Chi square tests for the Client Assessment Protocols, numerous significant 
differences were found between those who have had their medication regimes reviewed versus 
those who had not. The CAPS that differed significantly at the p < .05 level in order of 
decreasing Chi square values were Adherence, Environmental Assessment, Brittle Supports, 
Depression and Anxiety, Immunization and Screening, Behaviour, Cognition, Alcohol 
Dependence, Falls, Dehydration, Skin and Foot Conditions, Communication, Oral Health, 
Pressure Ulcers, and Reduction of Formal Services. Complete descriptions o f these CAPs as well 
as their triggering rules can be found within the RAI-HC Handbook (Morris et ah, 1999).
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The CAP where the greatest difference existed was Adherence. This CAP is defined as 
the extent to which a client's behaviour, in terms of taking medications, following diets, or 
executing lifestyle changes, coincides with medical or health advice. People who did not have 
their medications reviewed by a health professional in the last 180 days were more likely to have 
nonadherence to physician recommendations. This finding of a difference is not a surprising 
result as research into medication reviews has demonstrated that adherence can be significantly 
improved when reviews of medication regimes are given to patients receiving multiple 
prescriptions (Chumney & Robinson, 2006; Lefante et al., 2005).
A second CAP that showed significant difference for those with medication oversight is 
the Depression CAP. This CAP identifies the occurrence o f symptoms of depression. The clients 
with medication oversight on average triggered this depression cap more often than those who 
have had their medications reviewed. This is interesting as more research should look into 
depression and medication reviews as one cannot be sure if the depression causes one to miss out 
on medication reviews or if  inappropriate medications are the cause o f the depression or both.
Overall, these Chi square results inform us that differences exist for those with 
medication oversight exist when their health status is assessed. By looking at these differences, a 
general profile o f those who do not have their medications reviewed regularly is painted and 
more research should be performed in order to have a clear understanding of the factors involved 
for those patients who end up with a medication oversight. Further investigations may also 
determine the direction of causation (does the lack of having your medications reviewed increase 
the chance of depression; or, does depression increase the chance of not having your medications 
reviewed), and the extent of the effects. Of all the significant differences found in the CAPS, 
those with medication oversight were on the negative side o f each of those differences (re. Those
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with medication oversight were more likely to trigger the risk of falling CAP). This finding 
demonstrates that the lack of medication review does lead to negative effects on a number of 
different health measures.
A second set of analyses, /-tests, was performed to investigate the differences between 
those with and without medication oversight for the six health outcome measures. The results of 
the /-tests for the outcome measures indicated differences between those who have had their 
medication regimes reviewed and for those who had not for the MAPLe, CHESS, DRS, and 
CPS. In each of those four outcomes, the average score was higher for those who had not had 
their medications reviewed. This suggests that those who do not have their medications 
reviewed by a doctor for a extended period o f time are more likely to: (a) be placed into a long 
term care home as measured by the MAPLe; (b) show signs of depression as measured by the 
DRS; (c) have more cognitive impairment as measured by the CPS; and (d) have a higher risk of 
serious decline as measured by the CHESS. And again, these results demonstrate that the lack of 
a medication review leads to negative health outcomes. The relationship between medication 
oversight and the six outcome measures were further explored in this thesis by using mixed 
linear analyses.
From the results of the mixed linear analyses, the null models in each of the 6 outcomes 
revealed that the clustering effect o f the 14 CCACs exists and can be accounted for. The 
intraclass correlations ranged from .0018 (DRS) to .0248 (lADL Sum). Each of the outcomes 
examined in this thesis had results o f significant effects for the CCAC grouping variable. Thus, 
it is important for future studies to take such grouping effects into consideration when analyzing 
datasets containing multiple CCACs.
Exploring Medication Oversight 64
From the Model 1 analyses, all outcome variables were found to have a significant linear 
relationship with the centered medication oversight at time 2. The outcome variable that the 
centered medication oversight had its largest effect on was the Depression Rating Scale (t = 6.57, 
p  < .0001) followed by the MAPLe (/ = 5.90, p <.0001).
Social living circumstances (living alone), gender and age were significant predictors of 
all six of the health outcomes in model 3. The centered medication oversight at time 2 was 
found to be non significant for all of the six outcomes. Flowever, for the MAPLe, DRS, CPS and 
ADL Flier, the centered medication oversight at time 1 was a significant predictor o f higher 
scores on each outcome. Therefore, those who did not have their medications reviewed for the 
six months prior to first coming into contact with a CCAC were more likely to score higher each 
of those four measures. This implies that people whose medications are not reviewed by a 
doctor for 6 months prior to CCAC contact are more likely to: (a) be in need of long term care 
placement as measured by the MAPLe; (b) to have signs or symptoms of depression as measured 
by the DRS; (c) to have cognitive impairment as measured by the CPS; and (d) to depend on 
others for their activities o f daily living as measured by the ADL Flier.
The categorical number o f drugs variable (Drug Category) proved to be a significant 
predictor in 5 o f the 6 outcome variables. FFowever, its effect was not uniform in the way it 
predicted the scores. For the Depression Rating Scale, the CHESS, and the I ADL Sum, the 
higher the number of drugs the clients were taking, the lower the predicted scores were on these 
two scales. Conversely, for the MAPLe and Cognitive Performance Scale, the higher the 
number of drugs the clients were taking, the higher the predicted scores were on these three 
scales. Therefore, on average, those who were on a higher number of drugs displayed less signs 
of depression, less risk of decline, and less need to depend on a care taker for assistance with
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their instrumental aetivities o f daily living. Those on a lower number of drugs were more likely 
to have a need to be placed within a long-term care home and to show signs of eognitive 
impairment.
Strengths and Limitations
One of the major strengths of this study was the size of the dataset. Even after redueing the 
original dataset to examine only older adults who were in need of medication review, 
approximately 90 000 clients were analyzed. Secondly, another strength of this study was the 
use of proven health outcome measures. These outeome measures have been shown to be valid 
and reliable (Hirdes, Frijters, & Teare, 2003; Hirdes, Poss, & Curtin-Telegdi, 2008; Morris et al., 
1999; Burrows, Moris, Simon, Flirdes, & Phillips, 2000; Hartmaier et al., 1995; Morris et al.,
1999); This proven validity and reliability adds to the strength of the findings o f this study.
Despite the large size of the dataset, it may be diffieult to generalize the findings to a 
general population due to the faet the sample population were all clients within the CCAC 
system and from the province o f Ontario. This population eonsists of individuals who are using 
home eaie services, just released from aeute eare, and waiting for long-term eare.
A second limitation was the use o f routinely colleeted elinieal data. Due to the faet that 
medieation review is not the purpose of this tool, a number of important items related to 
medieation reviews such as timing of last review and who performed the review are not 
included. Also, beeause o f the way that the number of medieations a elient is on is colleeted on 
the MDS-HC, it is impossible to use that variable as a eontinuous one whieh limits not only the 
way it can be used in analyses, but also disallows any way to determine the true average o f the 
number o f medieations used in this population.
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Implications
From a research perspective, the implications of this study are the importance of using 
statistical methods that take into account the clustering effect of the 14 CCACs or geographical 
regions. The results of this thesis demonstrated this effect in that six out of six health outcome 
measures had significant clustering effects. Individual clients cannot be treated as completely 
separate entities as those living in the same region share a number o f characteristics that are 
unlike those in other regions.
The results of the Chi square tests indieate those who do not have their medications 
reviewed share a number of eharacteristics and with further study, a profile of such persons could 
be to discovered to aid CCACs in providing interventions to lower the occurrence of medication 
oversight.
Further research is required to examine the relationship between medieation oversight 
and the different health outcomes. Longitudinal research is predominantly required to determine 
the effect of not having one’s medications reviewed on health status over a long period of time.
A second area that is lacking in the literature is the association between medication 
oversight and inappropriate medications. With inappropriate medication rates being as high as 
they are, the effect of medication oversight on such medication use should be examined in all 
populations including home care, long term care and the general public.
Conclusion
To conclude, medication oversight when taking multiple medications should not occur, as 
it could be detrimental to one’s health to not have their medication regime reviewed by a 
qualified health professional regularly. As this study indicated, those who did not have their
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medications reviewed in the last 6 months on average had a higher risk of decline (CHESS 
score), more cognitive impairment (CPS score), more frequent symptoms of depression (DRS 
score), more dependence (ADL Hierarchy score) and a higher risk o f adverse outcomes (MAPLe 
score).
From the mixed linear analyses, differences between CCACs were found to exist. This 
finding implies that in the future, similar health research should take into account clustering 
effects when doing their analyses.
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